Emily’s primary collaboration is with Dr. Helena Furberg. Their work has focused on the impact of smoking intensity and duration on prognosis in urologic cancers including bladder and kidney cancer. They are also actively investigating the role of BMI and metabolic health on prognosis. Emily also collaborates with Dr. Colin Begg in developing statistical methods to assess etiologic heterogeneity. Together they have pursued analyses in both case-control as well as case-only settings and among both single primary and double primary cancers including melanoma, breast and kidney cancer. Finally, Emily works with Dr. Irina Ostrovnaya to investigate genetic and genomic predictive and prognostic factors in urologic cancers.